ATTO
NASDAQAttovia Therapeutics Inc.
Attovia Therapeutics Inc. (ATTO) is a Biotechnology: Biological Products (No Diagnostic Substances) company listed on NASDAQ. In the last 30 days Quantisnow tracked 2 wire items for ATTO, including 2 press releases and news items. The most recent was published Nov 5, 2026.
ATTO rankings
News · 26 weeks12+100%
2026-05-172026-11-08
Mix990d
- Analyst4(44%)
- Other4(44%)
- Offering1(11%)
Activity · 52 weeks128 active days
Tap a day to see what happenedEarningsInsiderAnalystFilings and news
Latest news
25 items- PRAttovia Therapeutics Announces Positive Topline 12-Week Results from Phase 1b Study of ATTO-1310 in Patients with Chronic Pruritus and High-Itch Atopic DermatitisResults build on preliminary Week 4 findings, in which a single dose of ATTO-1310 demonstrated rapid, deep, and durable itch relief in patients with chronic pruritus (CP) and high-itch atopic dermatitis (AD) The single dose also delivered skin lesion improvements that deepened through Week 12 in patients with high-itch AD Approximately 95% suppression of IL-31 through Week 12 supports potential for quarterly dosing Initiation of global Phase 2 trials of ATTO-1310 in patients with chronic pruritus of unknown origin (CPUO) and high-itch AD expected in 1H 2027 Company to host virtual KOL and clinical development update call today, November 5, 2026, at 4:30 pm ET SAN CARLOS, Calif
- PRAttovia Therapeutics to Participate in Upcoming Investor ConferencesSAN CARLOS, Calif., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Attovia Therapeutics, Inc. ("Attovia" or the "Company") (NASDAQ:ATTO), a clinical-stage biopharmaceutical company developing next-generation biotherapeutics for immune-mediated diseases with high unmet need, today announced that company management will participate in the following upcoming investor conferences: Guggenheim 3rd Annual Healthcare Innovation ConferenceFormat: Fireside chatDate: Tuesday, November 10, 2026Time: 3:30 PM - 3:55 PM ET Stifel 2026 Healthcare ConferenceFormat: 1x1 MeetingsDate: Wednesday, November 11, 2026 2026 Jefferies Global Healthcare Conference in LondonFormat: 1x1 MeetingsDate: Monday, November 16 – Wedne
- PRAttovia Therapeutics to Present New Data on ATTO-1310 and ATTO-2306 at EADV 2026 and Fall Clinical Dermatology Conference 2026SAN CARLOS, Calif., Sept. 28, 2026 (GLOBE NEWSWIRE) -- Attovia Therapeutics, Inc. ("Attovia") (NASDAQ:ATTO), a clinical-stage biopharmaceutical company developing next-generation biotherapeutics for immune-mediated diseases with high unmet need, today announced that it will present new clinical, translational, and preclinical data across its pipeline at the European Academy of Dermatology and Venereology (EADV) Congress 2026 and the Fall Clinical Dermatology Conference (FCD) 2026. Attovia will present four posters: three on ATTO-1310, a next generation anti-IL-31 ATTOBODY-based therapeutic, and one on ATTO-2306, a novel long-acting anti-IL-31 and IL-13 bispecific. The ATTO-1310 posters wi
- PRAttovia Therapeutics to Participate in Upcoming Investor ConferencesSAN CARLOS, Calif., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Attovia Therapeutics, Inc. ("Attovia" or the "Company") (NASDAQ:ATTO), a clinical-stage biopharmaceutical company developing next-generation biotherapeutics for immune-mediated diseases with high unmet need, today announced that company management will participate in the following upcoming investor conferences: Citi’s 2026 Biopharma Back to School ConferenceFormat: 1x1 meetings Date: Thursday, September 10, 2026 Morgan Stanley 24th Annual Global Healthcare ConferenceFormat: Fireside Chat Date: Wednesday, September 16, 2026Time: 10:00 AM - 10:35 AM EST The webcast of the Morgan Stanley fireside chat will be accessible on the investor
- PRAttovia Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate UpdateATTO-1310 demonstrated preliminary clinical proof of concept in chronic pruritus and high-itch atopic dermatitis (AD); complete Phase 1b data expected in Q4 2026 Phase 2 studies of ATTO-1310 in chronic pruritus of unknown origin and high-itch AD planned for 1H 2027 Phase 1 initiation for ATTO-2306 and ATTO-1091 planned in 1H 2027 Upsized Initial Public Offering (IPO) gross proceeds of $332.4 million helps extend cash runway into 2030 SAN CARLOS, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Attovia Therapeutics, Inc. ("Attovia" or the "Company") (NASDAQ:ATTO), a clinical-stage biopharmaceutical company developing next-generation biotherapeutics for immune-mediated diseases with high unme
- ANALYSTRBC Capital Mkts initiated coverage on Attovia Therapeutics with a new price targetRBC Capital Mkts initiated coverage of Attovia Therapeutics with a rating of Outperform and set a new price target of $45.00
- ANALYSTMorgan Stanley initiated coverage on Attovia Therapeutics with a new price targetMorgan Stanley initiated coverage of Attovia Therapeutics with a rating of Overweight and set a new price target of $39.00
- ANALYSTCitigroup initiated coverage on Attovia Therapeutics with a new price targetCitigroup initiated coverage of Attovia Therapeutics with a rating of Buy and set a new price target of $30.00
- ANALYSTLeerink Partners initiated coverage on Attovia Therapeutics with a new price targetLeerink Partners initiated coverage of Attovia Therapeutics with a rating of Outperform and set a new price target of $52.00
- PRAttovia Therapeutics Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional SharesSAN CARLOS, Calif., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Attovia Therapeutics, Inc. ("Attovia") (NASDAQ:ATTO), a clinical-stage biopharmaceutical company developing next-generation biotherapeutics for immune-mediated diseases with high unmet need, today announced the closing of its upsized initial public offering of 19,550,000 shares of its common stock, which includes the exercise in full by the underwriters of their option to purchase 2,550,000 additional shares, at the initial public offering price of $17.00 per share. The aggregate gross proceeds to Attovia from the initial public offering were approximately $332.4 million, before deducting underwriting discounts and commissions and other
- PRImmune Mediated Disease Therapeutics Developer Attovia Therapeutics Debuts on NasdaqSHANGHAI, Aug. 6, 2026 /PRNewswire/ -- Attovia Therapeutics, a portfolio company of Qiming Venture Partners and clinical-stage biopharmaceutical leader, successfully listed on the Nasdaq on August 5, 2026 Beijing time. Attovia Therapeutics (NASDAQ:ATTO) issued shares at a price of $17.00 per share and opened at $21.00 per share, with an approximate market capitalization of $904 million. Commencing operations in 2023, Attovia develops next‑generation biotherapeutics for immune‑mediated diseases with high unmet medical needs. All of Attovia's product candidates are discovered on its ATTOBODY biologics platform, which is licensed under an exclusive worldwide license from Alamar Biosciences, als
- PRAttovia Therapeutics Announces Pricing of Upsized Initial Public OfferingSAN CARLOS, Calif., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Attovia Therapeutics, Inc. ("Attovia") (NASDAQ:ATTO), a clinical-stage biopharmaceutical company developing next-generation biotherapeutics for immune-mediated diseases with high unmet need, today announced the pricing of its upsized initial public offering of 17,000,000 shares of its common stock at an initial public offering price of $17.00 per share. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses, are expected to be $289.0 million. All shares of common stock to be sold in the offering will be sold by Attovia. In addition, Attovia has granted the underwriters a
- SECSEC Form 6-K filed by Atento S.A.6-K - Atento S.A. (0001606457) (Filer)
- SECSEC Form 6-K filed by Atento S.A.6-K - Atento S.A. (0001606457) (Filer)
- SECSEC Form 6-K filed by Atento S.A.6-K - Atento S.A. (0001606457) (Filer)
- SECSEC Form 6-K filed by Atento S.A.6-K - Atento S.A. (0001606457) (Filer)
- SECSEC Form 6-K filed by Atento S.A.6-K - Atento S.A. (0001606457) (Filer)
- SECSEC Form 6-K filed by Atento S.A.6-K - Atento S.A. (0001606457) (Filer)
- SECSEC Form 6-K filed by Atento S.A.6-K - Atento S.A. (0001606457) (Filer)
- SECSEC Form 25-NSE filed by Atento S.A.25-NSE - Atento S.A. (0001606457) (Subject)
- PRAtento announces drawdown of $17 million in tranche 2 funding under its new interim financingTranche 2 upsized by $7 million to provide enhanced financial runway to support Atento's restructuring following substantial interest from existing investorsParticipation in Tranche 2 reflects incremental support for the Restructuring Support AgreementUpsizing of Tranche 2 financing brings total committed interim funding to the $37 million originally contemplatedNEW YORK, Aug. 1, 2023 /PRNewswire/ -- Atento S.A. (NYSE:ATTO, ", Atento", or the ", Company", ))), one of the world's largest providers of customer relationship and business process outsourcing (CRM/BPO) services and an industry leader in Latin America, today announced that it has received $17 million in tranche 2 funding under its
- SECSEC Form 6-K filed by Atento S.A.6-K - Atento S.A. (0001606457) (Filer)
- SECSEC Form EFFECT filed by Atento S.A.EFFECT - Atento S.A. (0001606457) (Filer)
- SECSEC Form POS AM filed by Atento S.A.POS AM - Atento S.A. (0001606457) (Filer)
- SECSEC Form S-8 POS filed by Atento S.A.S-8 POS - Atento S.A. (0001606457) (Filer)
ATTO FAQ
8 questionsWhat does Attovia Therapeutics Inc. do?
Attovia is a clinical-stage biopharmaceutical company developing next-generation biotherapeutics for immune-mediated diseases with high unmet need. All of its product candidates have been internally discovered using its ATTOBODY biparatopic biologics platform. Attovia's ATTOBODY platform uses an evolution-driven, high-throughput process that allows for rapid discovery and creation of a high diversity of potential product candidates. Attovia's lead programs include ATTO-1310, an anti-IL-31 therapeutic in clinical development for chronic pruritic diseases; ATTO-2306, a long-acting bispecific...What is the latest news on ATTO?
In the last 30 days Quantisnow tracked 2 wire items for ATTO: 2 press releases and news items. The most recent was published on November 5, 2026.Where does ATTO stock trade?
Attovia Therapeutics Inc. (ATTO) is listed on NASDAQ.What sector and industry is ATTO in?
Attovia Therapeutics Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did Attovia Therapeutics Inc. go public?
Attovia Therapeutics Inc. (ATTO) completed its IPO in 2014.What are analysts saying about ATTO?
Across the last 5 analyst actions on Attovia Therapeutics Inc., there was 1 upgrade and 0 downgrades. The most recent action was from RBC Capital Mkts: Outperform with a $45.00 price target on 2026-08-31. Recent price targets range from $30.00 to $52.00.What companies are similar to ATTO?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), MRNA (Moderna Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.). Compare ATTO side-by-side with any of them on Quantisnow.How can I track ATTO on Quantisnow?
Quantisnow aggregates Attovia Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ATTO to receive live email and push alerts on every new disclosure.